| Literature DB >> 36008981 |
Krystian Miazek1, Karolina Beton1, Agnieszka Śliwińska2, Beata Brożek-Płuska1.
Abstract
Prolonged elevated oxidative stress (OS) possesses negative effect on cell structure and functioning, and is associated with the development of numerous disorders. Naturally occurred anti-oxidant compounds reduce the oxidative stress in living organisms. In this review, antioxidant properties of β-carotene, tocopherols and ascorbic acid are presented based on in vitro, in vivo and populational studies. Firstly, environmental factors contributing to the OS occurrence and intracellular sources of Reactive Oxygen Species (ROS) generation, as well as ROS-mediated cellular structure degradation, are introduced. Secondly, enzymatic and non-enzymatic mechanism of anti-oxidant defence against OS development, is presented. Furthermore, ROS-preventing mechanisms and effectiveness of β-carotene, tocopherols and ascorbic acid as anti-oxidants are summarized, based on studies where different ROS-generating (oxidizing) agents are used. Oxidative stress biomarkers, as indicators on OS level and prevention by anti-oxidant supplementation, are presented with a focus on the methods (spectrophotometric, fluorometric, chromatographic, immuno-enzymatic) of their detection. Finally, the application of Raman spectroscopy and imaging as a tool for monitoring the effect of anti-oxidant (β-carotene, ascorbic acid) on cell structure and metabolism, is proposed. Literature data gathered suggest that β-carotene, tocopherols and ascorbic acid possess potential to mitigate oxidative stress in various biological systems. Moreover, Raman spectroscopy and imaging can be a valuable technique to study the effect of oxidative stress and anti-oxidant molecules in cell studies.Entities:
Keywords: antioxidants; biomarkers; oxidative stress; raman spectroscopy and imaging; reactive oxygen species
Mesh:
Substances:
Year: 2022 PMID: 36008981 PMCID: PMC9406122 DOI: 10.3390/biom12081087
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1The overview of oxidative stress (OS) generation in human, with various environmental factors as the cause of OS, with different ROS types and different intracellular sites for ROS generation, OS relation with the disease’s occurrence, and anti-oxidant mechanisms involving enzymatic and non-enzymatic molecules.
Exemplary structures of oxidation products of lipids, proteins and nucleic acids.
| Exemplary Structures of Oxidation Products | ||
|---|---|---|
| Name | Structure Description | Mechanism of Formation |
| Malondialdehyde (MDA) |
| PUFA peroxyl radical undergoes intramolecular cyclization to endoperoxide with further breakdown to MDA |
| 4-hydroxy-2-nonenal (4-HNE; HNE) |
| Peroxidation of n-6 PUFAs and the generation of α,β unsaturated aldehydes |
| Dityrosine |
| Generation of a tyrosyl radical, radical isomerization, diradical reaction, and enolization |
| HNE-Lys adduct (protein carbonyl product) |
| Michael addition of the HNE double bond to NH2-group of lysine (Lys) |
| HNE-Cys adduct (protein carbonyl product) |
| Michael addition of the HNE double bond to SH-group of cysteine (Cys) |
| HNE-His adduct (protein carbonyl product) |
| Michael addition of the HNE double bond to NH in an imidazole of histidine (His) |
| 8-oxo-2′-deoxyguanosine nucleotide |
| Reaction between C-8 of guanine (G) and hydroxyl radical (•OH) |
| 8-oxo-2′-deoxyadenosine nucleotide |
| Reaction between C-8 of adenine (A) and hydroxyl radical (•OH) |
| 5,6-dihydroxy-5,6-dihydrothymidine nucleotide |
| Reaction of hydroxyl radical (•OH) with C-5 and C-6 of thymine (T) |
| 5,6-dihydroxy-5,6-dihydrocytidine nucleotide |
| Reaction of hydroxyl radical (•OH) with C-5 and C-6 of cytosine (C) |
Figure 2The scavenging mechanism of provitamin A and vitamin A.
Figure 3The scavenging mechanism of α-tocopherol.
Figure 4The scavenging mechanism of ascorbate.
Figure 5Exemplary organic stress inducers used during in vitro and/or in vivo tests. Structures of glycochenodeoxycholic acid (A), aristolochic acid (B), t-BuOOH (C), dichlorvos (D), homocysteine (E), doxorubicin (F), methotrexate (G) and quinalphos (H).
Antioxidant activity of β-carotene towards oxidative stress (OS) induced in animal and human cells due to exposure to various stress agents.
| Antioxidant Effect of β-Carotene Towards OS-Induced Cells | ||||
|---|---|---|---|---|
| Cell Type | Oxidative Stress Inducer | Exposure Mode | Intracellular Effect | Ref. |
| Rat pheochromocytoma (PC12) cells (undifferentiated) | H2O2 | Incubation: 12 h without β-C and then 12 h with 40 µM H2O2 | ↑ | [ |
| Incubation: 12 h with 0.5–10 µM β-C and then 12 h with 40 µM H2O2 | ↓ | |||
| Rat hepatocytes | Glycocheno-deoxycholic acid (GCDC) | Incubation: 0.5 h without β-C and then 4 h with 100 µM GCDC | ↑ | [ |
| Incubation: 0.5 h with 50 µM β-C and then 4 h with 100 µM GCDC | ↓ | |||
| Oocytes | Rosup | Incubation: 4 h with 33.3 µg/mL Rosup | ↑ | [ |
| Incubation: 4 h with 10 µM β-C and 33.3 µg/mL Rosup | ↓ | |||
| Human erythrocytes | H2O2 | Incubation: 0.5 h with 20 µM H2O2 | ↑ | [ |
| Incubation: 0.5 h with 3 µM β-C and 20 µM H2O2 | ↓ | |||
| Mice erythrocytes | H2O2 | Incubation: 2 mM H2O2 | ↑ | [ |
| Incubation: 10 µg/mL β-C and 2 mM H2O2 | ↓ | |||
| Cardiomyocyte cells (H9c2) | AGEs | Incubation: 24 h with 200 µg/mL AGEs | ↑ | [ |
| Incubation: 24 h with 200 µg/mL AGEs + 24 h with 40 µM β-C | ↓ | |||
| Normal and tumor thymocytes | t-BuOOH | Incubation: 2 h with 0.5 mM t-BuOOH | ↑ | [ |
| Incubation: 0.5 h with β-C (2.8 nmol/mg dry wt) and 2 h with 0.5 mM t-BuOOH | ↓ | |||
—if compared to control without OS inducer used; —if compared to profile with OS inducer used; Measurement methods of ROS/oxidative stress markers: ROS: DCFA-DA; Lipid peroxidation: TBARS; MDA:TBA.
Antioxidant activity of tocopherols/vitamin E towards oxidative stress (OS) induced in animal and human cells due to exposure to various stress agents.
| Antioxidant Effect of Vitamin E towards OS-Induced Cells | ||||
|---|---|---|---|---|
| Cell Type | Oxidative Stress Inducer | Exposure Mode | Exposure Effect | Ref. |
| Human keratinocyte cells | UVA | Irradiation (UVA, 8 J/cm2) + incubation for 24 h | ↑ | [ |
| Incubation for 24 h with α-T (2.9–14.7 IU/mL), irradiation (UVA, 8 J/cm2) + incubation for 24 h | ↓ | |||
| Human neuroblastoma (SH-SY5Y) cells | AGEs | Incubation for 24 h without α-T, then incubation with 1.5 mg/mL AGEs for 72 h | ↑ | [ |
| Incubation for 24 h with α-T (200 µM), then incubation with 1.5 mg/mL AGEs for 72 h | ↓ | |||
| Human umbilical vein endothelial cells | Hcy | Incubation with Hcy (1 mM) | ↑ | [ |
| Incubation with Hcy (1 mM) and VitE (50 µM) | ↓ | |||
| Human erythrocytes | Dichlorvos (DDVP) | Incubation with DDVP (10 µM) | ↑ | [ |
| Incubation with DDVP (10 µM) and Vit E (30 µM) | ↓ | |||
| Human colorectal adenocarcinoma cell line (Caco-2) | H2O2 | Incubation for 24 h, incubation for 48 h with H2O2 (250 µM) | ↑ | [ |
| Incubation for 24 h, incubation for 48 h with H2O2 (250 µM) and VitE (10 µM) | ↓ | |||
| Rat hepatocytes | Glycocheno-deoxycholic acid | Incubation: 0.5 h without α-T and then 4 h with 100 µM GCDC | ↑ | [ |
| Incubation: 0.5 h with 100 µM α-T and then 4 h with 100 µM GCDC | ↓ | |||
| Rat renal tubular epithelial cells (NRK-52E) | Aristolochic acid (AA) | Incubation: AA (10 µM) | ↑ | [ |
| Incubation: AA (10 µM) + α-T (5–100 µM) | ↓ | |||
—if compared to control without OS inducer used; —if compared to profile with OS inducer used; Measurement methods of ROS/oxidative stress markers: ROS: DCFA-DA; Lipid peroxidation: TBARS; MDA: TBA; Protein carbonyls: Immunoblotting; H2O2: Chemiluminescence.
Antioxidant activity of ascorbic acid towards oxidative stress (OS) induced in animal and human cells due to exposure to various stress agents.
| Antioxidant Effect of Ascorbic Acid towards OS-Induced Cells | ||||
|---|---|---|---|---|
| Cell Type | Oxidative Stress Inducer | Exposure Mode | Exposure Effect | Ref. |
| Human embryonic kidney (HEK293) cells | H2O2 | Incubation: 4 h with H2O2 (400 µM) | ↑ | [ |
| Incubation: 24 h with Vit C (1–20 µM), and then 4 h with H2O2 (400 µM) | ↓ | |||
| Human lens epithelial cells (LEC) | H2O2 | Incubation: 24 h without VitC, and 0.5 h with H2O2 (0.2 mM) | ↑ | [ |
| Incubation: 24 h with VitC (1 mM), and 0.5 h with H2O2 (0.2 mM) | ↓ | |||
| Human retinal pigment epithelial (ARPE-19) cells | H2O2 or UVB | Incubation: UVB irradiation (20–100 mJ/cm2) | ↑ | [ |
| Incubation: 6 h with VitC (500 µM), then UVB irradiation (100 mJ/cm2) | ↓ | |||
| Human erythrocytes | Dichlorvos | Incubation with DDVP (10 µM) | ↑ | [ |
| Incubation with DDVP (10 µM) and Vit C (10 µM) | ↓ | |||
| Human hepatoma (HepG2) cells | Ethanol, sodium selenite or t-BuOOH | Incubation with ethanol (10–500 µM) or sodium selenite (1–10 µM) or t-BuOOH (20–200 µM) for 24 h | ↑ | [ |
| Cotreatment with Vit C (25–100 µM) and one of OS inducer for 24 h | ↓ | |||
| Human skin fibroblasts (CCD 1112Sk) | UVA, UVB or H2O2 | For irradiation treatment: 20 J/cm2 (UVA) or 200 mJ/cm2 (UVB) + 24 h incubation; For H2O2 treatment: incubation with 200 µM H2O2 for 24 h | ↑ | [ |
| Stress induction treatment + 24 h incubation with 100 µM ascorbic acid | ↓ | |||
| Rat renal tubular epithelial cells (NRK-52E) | Aristolochic acid (AA) | Incubation: AA (10 µM) | ↑ | [ |
| Incubation: AA (10 µM) + Vit C (5 µM) | ↓ | |||
—if compared to control without OS inducer used; —if compared to profile with OS inducer used; Measurement methods of ROS/oxidative stress markers: ROS: DCFA-DA, ESR [197]; MDA:TBA, GC-MS [197]; 4-HNE: GC-MS [197]; Isoprostanes: LC-MS [197]; Protein carbonyls: DNPH; 8-OHdG: ELISA [193], LC-MS [197]; H2O2: Chemiluminescence.
Figure 6The structures of provitamin A (β-carotene) and vitamin A constituents (retinaldehyde, retinol, retinoic acid).
Antioxidant activity of β-carotene, vitamin E and/or vitamin C based on animal in vivo studies with different oxidative stress inducers applied.
| Antioxidant Effect of β-Carotene, Vitamin E and/or Vitamin C In Vivo | ||||
|---|---|---|---|---|
| Species/Tissue | Oxidative Stress Inducer | Exposure Mode | Exposure Effect | Ref. |
| Wistar rats | Methotrexate (MTX) | Single MTX dose (20 mg/kg) on day 21 of experiment (24 days) | ↑ | [ |
| β-C dose (10 mg/kg/day) for 24 days + MTX dose (20 mg/kg) on day 21 | ↓ | |||
| Wistar rats | High-fat diet (HFD) (Mixing of cow fat (60%) with normal rat chow (40%)) | HFD for 14 weeks + 24 h starving | ↑ | [ |
| β-C administration (300 mg/kg body weight) for 2 weeks before or after 12-week HFD + 24 h starving | ↓ | |||
| Male Sprague–Dawley rats n = 299 (total)/Spinal Cord tissue | Spinal Cord Injury (SCI) | SCI surgery + 72 h | ↑ | [ |
| SCI surgery + β-C (20–80 mg/kg) administered intraperitoneally once immediately after the surgery + 72 h | ↓ | |||
| Male C57BL/6 mice n = 108 (total)/Brain tissue | Traumatic Brain Injury (TBI) | TBI surgery + 7 days | ↑ | [ |
| TBI surgery + β-C (30 mg/kg) administered 3 h after the surgery and then every day during 7 days | ↓ | |||
| Gamma irradiation | Exposure to 10 Gy γ-irradiation | ↑ | [ | |
| Larvae feeding on β-C before exposure to 10 Gy γ-irradiation | ↓ | |||
| Wistar male rats n = 60 (total)/Serum | Cd2+ (CdCl2·H2O) | Single intraperitoneal injection of Cd2+ ions (2 mg Kg−1) | ↑ | [ |
| Single intraperitoneal injection of Cd2+ ions (2 mg/Kg) + administration of drink aqueous solutions of α-T (40 mg/L) for 15 days | ↓ | |||
| Male Sprague–Dawley rats n = 70 (total)/Heart tissue | Doxorubicin (DOX) | Intraperitoneal injection (4 mg DOX/ | ↑ | [ |
| Intra-gastric administration (100 mg VitE/kg body weight), two times per week for 3 weeks, started 1 week before DOX injection | ↓ | |||
| Female white mice n = 160 (total)/Blood | Cyfluthrin | Oral administration of cyfluthrin (a single dose of 100 mg/kg/body weight) | ↑ | [ |
| Oral administration of cyfluthrin (a dose of 100 mg/kg/body weight) followed by intramuscular injection of VitE (a dose of 100 mg/kg/body weight, for 7 days) | ↓ | |||
| C57BL/6 mice/Infarcted tissue | Ischemia/Reperfusion (I/R) injury | I/R injury + 3 days | ↑ | [ |
| Intraperitoneal injection of α-TOH (2.5 mg/kg BW) 2 h before surgery, immediately after reperfusion and twice per day for 3 days | ↓ | |||
| BALB/c mice n = 40 (total)/Heart tissue | Heat stress (HS) | HS conditions (temperature: 40 °C; humidity: 60%) for 4 h per day during a 4-week period | ↑ | [ |
| Oral administration of VitE (500 mg/kg) 2 h before the initiation of HS | ↓ | |||
| Sprague-Dawley male rats n = 30 (total)/Blood | High-fat diet | A 10-week feeding on high-fat diet | ↑ | [ |
| A 10-week feeding on high-fat diet supplemented with VitE (350 mg/kg diet) | ↓ | |||
| Ross 308 male broilers (21-day old) n = 400 (total)/Blood, Breast muscle | High n-3 dietary PUFAs intake | Chickens fed with commercial starter diet (1–12 days), commercial grower diet (13–20 days), finisher diet enriched with 5% cold-pressed linseed oil and supplemented with VitE (200 IU/kg) (21–40 days) | ↓ | [ |
| Wistar rats n = 28 (total)/Stomach, Colon, Kidney tissue | Sodium azide (NaN3) | Oral administration of NaN3 (20 mg/kg BW) for 9 days | ↑ | [ |
| Oral administration of NaN3 and VitC (200 mg/kg BW) for 9 days | ↓ | |||
| Wistar male rats n = 46/Heart tissue | Doxorubicin (DOX) | Six intraperitoneal DOX injections (2.5 mg/kg body wt) over 3 weeks | ↑ | [ |
| Oral daily administration of VitC (50 mg/kg) started 1 week before the start of DOX administration and continued for 2 weeks after the last DOX injection | ↓ | |||
| Sprague–Dawley male rats n = 18 (total)/Heart tissue | Quinalphos (QP) | Oral dose of QP (14 mg/kg), daily for 10 days | ↑ | [ |
| Oral administration of VitC (20 mg/kg) daily, 4 h after QP administration, for 10 days | ↓ | |||
—if compared to control without OS applied; —if compared to profile with OS applied; —if compared to profile without anti-oxidant applied; Measurement methods of ROS/oxidative stress markers: Lipid peroxidation: TBARS; MDA: TBA; Protein carbonyls: DNPH, Oxidized lipids: LC-MS; Superoxide anion: Adrenaline assay.
Antioxidant activity of β-carotene, vitamin E and/or vitamin C based on populational/clinical studies.
| Antioxidant Effect of β-Carotene, Vitamin E and/or Vitamin C in Human Studies | ||||
|---|---|---|---|---|
| Patients/Participants | Origin of Oxidative Stress | Treatment Mode | Treatment Effect | Ref. |
| Male workers exposed to lead, n = 85 (total)/Blood | Pb | No administration of antioxidants for 12 weeks | - | [ |
| Oral administration of β-carotene (10 mg/day) for 12 weeks | ↓ | |||
| Patients with NIDDM, n = 20 (total)/Blood | NIDDM | Supplementation with β-carotene (60 mg/day) for 3 weeks | ↓ | [ |
| Participants with polygenic hypercholesterolemia, n = 35/Blood | Enhanced oxidative stress | Supplementation with placebo for 16 weeks | - | [ |
| Supplementation with VitE (1600–3200 I.U.) for 16 weeks | ↓ | |||
| White volunteers, n = 8 (total)/Skin | UVR | Supplementation with α-tocopherol (400 IU/day) for 8 weeks, skin exposure to UVR (120 mJ/cm2), skin biopsy 6 h after UVR exposure | ↓ | [ |
| Participants at age of 77, n = 704/Urine | n.d. | Dietary intake of ascorbic acid and β-carotene | ↓ | [ |
| Female participants with type 2 diabetes, n = 34 (total)/Blood | Type 2 diabetes | Oral administration of placebo (800 mg/day) for 6 weeks | - | [ |
| Oral administration of α-tocopherol (800 IU/day) for 6 weeks | ↓ | |||
| Participants with DMT2, n = 5 or 8 (total)/Blood | DMT2 | Supplementation with VitC (1000 mg/day) for 6 weeks | ↓ | [ |
| Participants with DMT2 and administered with hypoglycemic drug, n = 80 (total)/Blood | DMT2 | No supplementation of VitE within 3 months | ↑ | [ |
| Supplementation of VitE (400 mg/day) for 3 months | ↓ | |||
| Patients with late-stage knee osteoarthritis, n = 72 (total)/Blood, synovial fluid | Enhanced oxidative stress | Oral administration of placebo once daily for 2 months | - | [ |
| Oral administration of VitE (400 IU/day) for 2 months | ↓ | |||
—if compared to the beginning of the study; —if compared to profile without antioxidant used; —if compared to control: normoglycemic profile; —if compared to control: healthy subjects; —if compared to lower intake of antioxidants; Measurement methods of oxidative stress biomarkers: MDA: TBA; LHP: FOX assay; F2-Isoprostanes: GC-MS [227], Radioimmunoassay [229], ELISA [231].
Figure 7The microscopy image of exemplary CCD-18Co cell (A), Raman image constructed based on Cluster Analysis (CA) method (B), Raman images of all clusters identified by CA assigned to: nucleus (red), mitochondria (magenta), lipid-rich regions (blue, orange), membrane (light grey), cytoplasm (green), and cell environment (dark grey) (C), average Raman spectra typical for all clusters identified by CA in a 500–1800 cm−1 (D) and a 2700–3100 cm−1 (E) wavenumber region, average Raman spectrum for the whole cell within 500–3100 cm−1 (F); cells measured in PBS, excitation wavelength: 532 nm. Reprinted with permission from [277].
Figure 8Raman spectroscopy analysis of cells exposed to t-BuOOH, β-carotene and/or Vit C; Raman image of CCD-18Co exemplary cells (A), average Raman spectra of exemplary CCD-18Co cell (B), Raman I1004/1254 (C) and Raman I1254/1656 (D) graph values with bars: control, t-BuOOH, t-BuOOH + β-C, Raman I1004/1078 (E) and Raman I1004/1658 (F) graph values with bars: control, t-BuOOH, t-BuOOH + Vit C. Reprinted and adapted with permission from [277,278].